MedTrace Logo

Safety and Efficacy Study of NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) and Systemic Inflammation

NCT02794857 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2018-05-07

No results posted yet for this study

Summary

This study evaluates NP001 in patients with amyotrophic lateral sclerosis (ALS) and evidence of systemic inflammation. Half of participants will receive NP001 and the other half will receive placebo.

Conditions

Interventions

DRUG

NP001

DRUG

Placebo

Sponsors & Collaborators

  • Neuraltus Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Gil Block, MD, PhD · Neuraltus Pharmaceuticals, Inc.

  • Robert G. Miller, MD · California Pacific Medical Center

  • Jonathan Katz, MD · California Pacific Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-29
Primary Completion
2017-12-12
Completion
2017-12-12

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02794857 on ClinicalTrials.gov